课题基金 / 基金详情

TRITIUM LABELLING OF DOPAMINE AGONIST: SCHIZOPHRENIA

TRITIUM LABELLING OF DOPAMINE AGONIST: SCHIZOPHRENIA
多巴胺激动剂的氚标记:精神分裂症
批准号:
6220446
负责人:
HIROMI MORIMOTO
金额:
$0.78万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-08-01 至 2000-07-31

项目摘要

项目成果

HIROMI MORIMOTO的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This chemical compound is being synthesized by SRI for Dr. R.A. Lahti, B00. of Psychiatry at Maryland School of Medicine. The study of dopamine D4 receptors subtypes is important because of their possible involvement in schizophrenia (we have reported increases in the D4 receptor in schizophrenic brains), attention deficit disorders, and drug addiction. N-0437 is the only chemically stable, full dopamine D2-type agonist available. It binds with high affinity to the dopamine D2, D3 and D4 receptors. Ligands such as 3H apomorphine and dopamine also bind in this manner but are highly unstable and readily oxidize in solution, thus requiring the use of antioxidants such as ascorbic acid which can interfere with binding. 3H(-)NPA is also available but is a partial agonist at the D4 receptor. The (-) enantiomer of N-0347 (Dr. W. Timmerman's PhD Thesis) is a high affinity partial agonist of the dopamine D2-type receptor. In contrast (-)N-0437 is a full agonist acting at high affinity at all D2-type receptors. We developed a procedure (Mol. Pharm. 42:432-438 (1992)) using a 3H agonist and a 3H antagonist to determine whether drugs are agonists, partial agonist, or antagonists at various G protein-coupled receptors. In those studies we used [3H]U-86170, which was obtained from the Upjohn Company. Unfortunately, both [3H]U-86170 and [3H] N-0437 are no longer available. Requests have been made to NEN, Amersham and Tocris to prepare [3H] N-0437, but they were unsuccessful. 3H(-) N-0437 will be a very useful radioactive full agonist ligand, and is the preferred ligand since it binds with high affinity to all the D2-type receptors. User Details: Experiment Details: User Number: 1711 Tritiation City, State: Menlo Park, CA HPLC Funding Source: NIH 3 N01 MH80015 NMR Charge: $3539.46 2 days Program Income: $3539.46 (projected) 1 compound
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TRITIUM LABELLING OF APTAMERS: MACULAR DEGENERATION
SYNTHESIS OF SPECIFICALLY LABELLED NICOTINE COMPOUND: PARKINSON'S & ALZHEIMER'S
STEREOCHEMISTRY OF POLYKETIDE BIOSYNTHESIS
TRITIUM LABELLING OF ALZHEIMER DRUG
海外基金